menu
    • menu

    Company profile for Asher Biotherapeutics

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    At Asher Biotherapeutics, we are pioneering a new approach with our cis‑targeted immunotherapies. Our immunotherapies selectively activate only the immune cell types that drive the desired therapeutic response. With this innovation, we address an inherent shortcoming of conventional immunotherapies, which indiscriminately act on multiple cell types, resulting in suboptimal efficacy and side effects.Our approach has the poten...
    At Asher Biotherapeutics, we are pioneering a new approach with our cis‑targeted immunotherapies. Our immunotherapies selectively activate only the immune cell types that drive the desired therapeutic response. With this innovation, we address an inherent shortcoming of conventional immunotherapies, which indiscriminately act on multiple cell types, resulting in suboptimal efficacy and side effects.Our approach has the potential to precisely direct different immune mediators against a range of target immune cell-types and create best-in-class immunotherapies in cancer, autoimmune and infectious diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Asher BiotherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    650 Gateway Blvd. Suite 100 South San Francisco, CA 94080
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://asherbio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/asher-biotherapeutics/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/asherbio

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Asher Bio Partners With Etakafusp Alfa For SCLC Trials
    Asher Bio Partners With Etakafusp Alfa For SCLC Trials

    08 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250108653273/en

    BUSINESSWIRE
    08 Jan 2025
    Share Share
    Asher Bio To Evaluate Etakafusp Alfa In NSCLC Phase 1b/2 Study
    Asher Bio To Evaluate Etakafusp Alfa In NSCLC Phase 1b/2 Study

    07 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250107837910/en

    BUSINESSWIRE
    07 Jan 2025
    Share Share
    Asher Bio $55M Series C For Lead Program Phase 1b
    Asher Bio $55M Series C For Lead Program Phase 1b

    16 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240416383585/en

    BUSINESSWIRE
    16 Apr 2024
    Share Share
    Asher Announces Publications of AB248, its CD8+ T Cell Selective IL-2 Candidate
    Asher Announces Publications of AB248, its CD8+ T Cell Selective IL-2 Candidate

    03 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240403307420/en

    BUSINESSWIRE
    03 Apr 2024
    Share Share
    Asher drops 60% of staff to zero in on lead immunotherapy
    Asher drops 60% of staff to zero in on lead immunotherapy

    19 Dec 2023

    // Annalee Armstrong FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/asher-drops-60-staff-immunotherapy-biotech-zeroes-lead-candidate

    Annalee Armstrong FIERCE BIOTECH
    19 Dec 2023
    Share Share
    Asher Bio Presents Promising New Preclinical Data for AB821 at SITC
    Asher Bio Presents Promising New Preclinical Data for AB821 at SITC

    31 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231031616711/en

    BUSINESSWIRE
    31 Oct 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search